Phase Ii Study Of I-131-Mibg With Vincristine And 5 Days Of Irinotecan For Patients With Relapsed Or Refractory Neuroblastoma.

10033 Background: 131I-metaiodobenzylguanidine (MIBG) is a targeted radiopharmaceutical active in neuroblastoma. A previous study demonstrated that MIBG (18 mCi/kg) could be combined with vincristine and irinotecan (20 mg/m2/dose for 5 days/week x 2 weeks) as a radiation sensitizer. However, 25% of courses were associated with grade 3 diarrhea. To reduce the incidence of diarrhea, the current study evaluated MIBG together with vincristine and 5 days of higher-dose irinotecan, a standard schedule in recent pediatric trials. This report describes the experience with this regimen at maximum tolerated MIBG dose of 18 mCi/kg. Methods: Patients 6 months from prior MIBG and u003c 18 mCi/kg cumulative prior dose. Patients received cefixime on days -1 to +6, irinotecan (50 mg/m2/dose IV) on days 0-4, and vincristine (2 mg/m2) on day 0. MIBG (18 mCi/kg) was given on day 1 ...